Precision monitoring for oncology drug development
Detect what imaging misses. Act before relapse.
Molecular/Minimal Residual Disease (MRD) is redefining how biopharma teams evaluate treatment response, stratify patients, and accelerate clinical development. By identifying microscopic diseases below radiographic detection, MRD provides early, actionable insight into therapeutic efficacy and relapse risk.
Cellular + molecular. One unified solution.
We offer two MRD technologies to support clinical and translational programs across hematologic and solid tumors.
- Flow cytometry-based MRD
- NGS-based MRD
CTA style
Default